Abstract |
We retrospectively analyzed 44 patients undergoing first-line treatment for mantle cell lymphoma with R-HyperCVAD, with or without rituximab (R) maintenance or auto-SCT. The primary study end point was PFS; secondary end point was overall survival.Median follow up for all patients was 3.3 years. Median age was 54 years, and 95% (n=42) were stage III or IV at diagnosis. In all, 17 patients underwent consolidative auto-SCT and 12 patients received R maintenance. The overall response rate was 95%, with 91% achieving complete response (CR). Median PFS for all patients was 3.5 years. Median PFS was 2.3 years for patients treated with R-HyperCVAD alone vs 3.9 years (P=0.02) with R-HyperCVAD+ R maintenance and 4.5 years (P=0.01) with R-HyperCVAD+ auto-SCT. For patients who did not achieve CR at interim staging, PFS for R-HyperCVAD alone was 1.4 years vs not reached for R-HyperCVAD+ consolidation (either R maintenance or auto-SCT) (P=0.02). PFS for patients with CR at interim staging was 3.3 years vs not reached (P=0.04) after consolidation. Our data suggest potential improvement in PFS when R-HyperCVAD is consolidated with either R maintenance or auto-SCT. This benefit appears particularly significant in those patients who do not achieve CR at interim restaging.
|
Authors | T Ahmadi, J McQuade, D Porter, N Frey, A W Loren, S C Goldstein, J Svoboda, E Stadtmauer, S J Schuster, S D Nasta |
Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 47
Issue 8
Pg. 1082-6
(Aug 2012)
ISSN: 1476-5365 [Electronic] England |
PMID | 22080969
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- Rituximab
|
Topics |
- Antibodies, Monoclonal, Murine-Derived
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Lymphoma, Mantle-Cell
(mortality, pathology, therapy)
- Male
- Middle Aged
- Neoplasm Staging
- Retrospective Studies
- Rituximab
- Stem Cell Transplantation
- Survival Rate
- Time Factors
- Transplantation, Autologous
|